However, CK2 inhibition was found effective in malignant glial tumors, without any restriction to the p53 status [83]; this was in agreement with a study that exploited isogenic colon adenocarcinoma cell lines differing in the presence or absence of p53 to demonstrate that the enhancement of Apo2L/TRAIL-induced apoptosis by CK2 inhibitors is independent of p53 [91]. The gene discussed is TP53; the disease is malignant glioma.